The corona virus reached Saxony last week. The number of infections is also increasing in Bavaria. "According to the current risk assessment, we have to learn to live with this virus," says Dr. Nicole Porzig, deputy crisis manager in DRK Saxony. "Until an antidote is found, the population must be informed promptly and reliably," says Dr. Porzig further.
In cooperation with the AI startup DOCYET from Leipzig, the DRK is breaking new ground. For the first time, the Red Cross is using a chat bot, i.e. a text-based dialogue system that can communicate with users. This chat bot provides simple and up-to-date information about the corona virus, carries out a suspicion test based on simple questions and provides information about the care options in your own area. This is intended to relieve the existing telephone information channels and medical practices.
In addition, on the website you will find:
1. Information signs for private use, but also for companies and institutions that anyone can print out.
2. A news ticker that filters current reports on the subject of the corona virus in Saxony from the Internet.
3. Information on where and to what extent Saxon Red Cross helpers have been deployed so far.
4. Information on how you can support the work of the DRK in Saxony.
For further information and inquiries please contact Dr. Kai Kranich at 0351 – 4678104 or firstname.lastname@example.org.
Source: Press release DRK Landesverband Sachsen eV from 09.03.2020
For many decades, scientists at the University of Leipzig have been researching the causes, diagnosis and therapy of Alzheimer's disease. Now a team led by Prof. Dr. Thomas Arendt from the Paul Flechsig Institute for Brain Research in genome and transcriptome analyzes show that the genes with altered activation in Alzheimer's were subject to evolutionary biological adaptations in the recent phylogenetic past. This makes Alzheimer's a human-specific disease that can only be simulated in animal experiments to a very limited extent. The researchers recently published these results in the journal Molecular Psychiatry.
c-LEcta, a global biotechnology company with technology leadership in the areas of enzyme engineering and bioprocess development for regulated markets such as the food and pharmaceutical industries, is entering into a development partnership with the MDax company Symrise. Founded in 2003, Symrise AG is one of the world's leading suppliers of fragrances and flavorings.